Literature DB >> 27826561

Comment on "combination treatment including targeted therapy for advanced hepatocellular carcinoma".

Lijun Zhang1, Guangming Li1.   

Abstract

Entities:  

Year:  2016        PMID： 27826561      PMCID： PMC5075827          DOI： 10.21037/hbsn.2016.10.01

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  15 in total

1.  Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.

Authors:  Maxime Ronot; Mohamed Bouattour; Johanna Wassermann; Onorina Bruno; Chantal Dreyer; Béatrice Larroque; Laurent Castera; Valérie Vilgrain; Jacques Belghiti; Eric Raymond; Sandrine Faivre
Journal:  Oncologist       Date:  2014-03-20

Review 2.  Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.

Authors:  Helena Linardou; Issa J Dahabreh; Dimitra Kanaloupiti; Fotios Siannis; Dimitrios Bafaloukos; Paris Kosmidis; Christos A Papadimitriou; Samuel Murray
Journal:  Lancet Oncol       Date:  2008-09-17       Impact factor: 41.316

3.  Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.

Authors:  Shao-Lai Zhou; Zheng-Jun Zhou; Zhi-Qiang Hu; Xiao-Wu Huang; Zheng Wang; Er-Bao Chen; Jia Fan; Ya Cao; Zhi Dai; Jian Zhou
Journal:  Gastroenterology       Date:  2016-02-26       Impact factor: 22.682

4.  ADRB2 signaling promotes HCC progression and sorafenib resistance by inhibiting autophagic degradation of HIF1α.

Authors:  Fu-Quan Wu; Tian Fang; Le-Xing Yu; Gui-Shuai Lv; Hong-Wei Lv; Dong Liang; Ting Li; Chang-Zheng Wang; Ye-Xiong Tan; Jin Ding; Yao Chen; Liang Tang; Lin-Na Guo; Shan-Hua Tang; Wen Yang; Hong-Yang Wang
Journal:  J Hepatol       Date:  2016-05-03       Impact factor: 25.083

5.  Cancer statistics, 2015.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-01-05       Impact factor: 508.702

6.  Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA.

Authors:  John P Duffy; Andrew Vardanian; Elizabeth Benjamin; Melissa Watson; Douglas G Farmer; Rafik M Ghobrial; Gerald Lipshutz; Hasan Yersiz; David S K Lu; Charles Lassman; Myron J Tong; Jonathan R Hiatt; Ronald W Busuttil
Journal:  Ann Surg       Date:  2007-09       Impact factor: 12.969

7.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

Authors:  Ann-Lii Cheng; Yoon-Koo Kang; Zhendong Chen; Chao-Jung Tsao; Shukui Qin; Jun Suk Kim; Rongcheng Luo; Jifeng Feng; Shenglong Ye; Tsai-Sheng Yang; Jianming Xu; Yan Sun; Houjie Liang; Jiwei Liu; Jiejun Wang; Won Young Tak; Hongming Pan; Karin Burock; Jessie Zou; Dimitris Voliotis; Zhongzhen Guan
Journal:  Lancet Oncol       Date:  2008-12-16       Impact factor: 41.316

8.  In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer.

Authors:  Ramona Rudalska; Daniel Dauch; Thomas Longerich; Katherine McJunkin; Torsten Wuestefeld; Tae-Won Kang; Anja Hohmeyer; Marina Pesic; Josef Leibold; Anne von Thun; Peter Schirmacher; Johannes Zuber; Karl-Heinz Weiss; Scott Powers; Nisar P Malek; Martin Eilers; Bence Sipos; Scott W Lowe; Robert Geffers; Stefan Laufer; Lars Zender
Journal:  Nat Med       Date:  2014-09-14       Impact factor: 53.440

9.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

Review 10.  Combination treatment including targeted therapy for advanced hepatocellular carcinoma.

Authors:  Jianzhen Lin; Liangcai Wu; Xue Bai; Yuan Xie; Anqiang Wang; Haohai Zhang; Xiaobo Yang; Xueshuai Wan; Xin Lu; Xinting Sang; Haitao Zhao
Journal:  Oncotarget       Date:  2016-10-25
View more
  1 in total

Review 1.  Brain metastases from hepatocellular carcinoma: recent advances and future avenues.

Authors:  Shanshan Wang; Anqiang Wang; Jianzhen Lin; Yuan Xie; Liangcai Wu; Hanchun Huang; Jin Bian; Xiaobo Yang; Xueshuai Wan; Haitao Zhao; Jiefu Huang
Journal:  Oncotarget       Date:  2017-04-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.